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Background: Currently the majority of cancer patients are considered ineligible for intensive care treatment and
oncologists are struggling to get their patients admitted to intensive care units. Critical care and oncology are
frequently two separate worlds that communicate rarely and thus do not share novel developments in their fields.
However, cancer medicine is rapidly improving and cancer is eventually becoming a chronic disease. Oncology is
therefore characterized by a growing number of older and medically unfit patients that receive numerous novel
drug classes with unexpected side effects.
Discussion: All of these changes will generate more medically challenging patients in acute distress that need to
be considered for intensive care. An intense exchange between intensivists, oncologists, psychologists and
palliative care specialists is warranted to communicate the developments in each field in order to improve triage
and patient treatment. Here, we argue that “critical care of cancer patients” needs to be recognized as a medical
subspecialty and that there is an urgent need to develop it systematically.
Conclusion: As prognosis of cancer improves, novel therapeutic concepts are being introduced and more and
more older cancer patients receive full treatment the number of acutely ill patients is growing significantly. This
development a major challenge to current concepts of intensive care and it needs to be redefined who of these
patients should be treated, for how long and how intensively.
Background
The discovery of the human genome and the develop-
ment of high-power bioinfomatics tools have led to an
exponential growth of biomedical knowledge. One of
the areas that has benefited the most over the last few
years has been cancer research which is now translating
into a dramatic development of clinical oncology. As a
result targeted therapy and personalized medicine will
eventually transform cancer into a chronic or even cur-
able disease.
While improved overall survival and reduced acute
toxicities are already visible in certain, defined clinical
scenarios [1-3], secondary consequences such as long-
term toxicities, quality of life, long-term cancer survivor-
ship, the role of palliative care etc. need to be addressed
in novel research programs. The growing complexity of
cancer medicine has led to the development of
comprehensive cancer centers, institutions designed to
bring multi-disciplinary care to the patient ensuring all
important angles of diagnostics and therapy are covered.
Here, we propose that one of the most striking conse-
quences is the urgent need for new critical care con-
cepts for cancer patients. This hypothesis is supported
by the following arguments:
Some cancers are likely to become a chronic disease.
However, in accordance with current recommendations
advanced stage cancer patients are frequently denied
admission by intensive care units that are normally run
by non-oncologists [4-6]. When a given patient’sl i f e
expectancy increases from three months to three years
these concepts are radically challenged: How many ICU
or respirator days are reasonable? How aggressive
should such a treatment be: Is non-invasive ventilation
the maximum support or can select cases be identified
where extracorporeal respiratory devices such as ECLA
(extra corporal lung assist device) or ECMO (extra cor-
poral membrane oxygenization) will be a reasonable
choice? Is a five-agent-vasopressor-therapy in principle
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in a slowly progressive colon cancer patient on bevaci-
zumab/capecitabine with an ECOG-1 (Eastern Coopera-
tive Oncology Group) performance since diagnosis five
years ago receive extensive treatment?
When critical care comes into play does palliative
care need to step back or even come closer? In termin-
ally ill lung cancer patients for example the frequency of
end-of-life-admissions to hospices as well as ICUs have
been reported to increase substantially suggesting that
both specialities are needed for this patient cohort [7].
Early involvement of palliative care teams in the treat-
ment of pediatric cancer patients has demonstrated to
reduce unnecessary full codeo r d e r sa n de a s es u f f e r i n g
[8]. This emphasizes the rarely appreciated interphase
between two distinct medical specialities that must enter
into a continuous dialogue to develop a culture of com-
mon patient-family discussions, consultations and opti-
mization of treatment practice.
In cancer patients neutropenia, autologous bone mar-
row transplantation and the characteristics of the under-
lying malignancy now have limited influence on the acute
outcome while the number of organ failures and severity
of infection are correlate with survival [9-12]. ICU survi-
val of cancer patients has been shown to improve over
time [13-16]. Even survival after cardiopulmonary resus-
citation of cancer patients compares favorably to unse-
lected patients [17]. However, triage of critically ill cancer
patients using classic scoring systems appears to be diffi-
cult as they are not developed for this cohort and often
lead to wrong predictions. Therefore, they are the subject
of an ongoing debate and further improvement appears
necessary [18-22]. Even cancer-specific scores such as the
Cancer Mortality Model are not widely used as they
appear not to improve mortality prediction [20,22].
This is of particular importance as the treating physi-
cian’s perception of a critically ill patient’s prognosis has
been shown to influence survival more strongly than the
baseline disease severity, development of organ dysfunc-
tion or use of vasopressors [23]. The prognosis of criti-
cally ill cancer patients is generally perceived to be
extremely poor by most physicians. Consequently, criti-
cally ill cancer patients might often be refused intensive
care. However, a recent study showed a high mortality
in ill cancer patients who were considered to be too
well for ICU admission while patients who were consid-
ered to be too sick could benefit from ICU admission
[24]. A reappraisal of ICU admission criteria for cancer
patients is therefore required. Triage decisions solely
based on the type of cancer are thus not justified but
instead should be made by an interdisciplinary team
consisting of intensivists, medical and surgical oncolo-
gists with experience in treating critically ill cancer
patients.
Life expectancy is rising globally and in 2025 1.2 billion
people will be older than 60 years of age [25]. Therefore,
more and more older people will be treated long-term
for cancer bringing clinical problems of internal and ger-
iatric medicine into the world of cancer treatment [26].
So far patients with significant co-morbidities or higher
age are rarely treated intensively and complex operations,
high-dose chemotherapies and stem cell transplantation
are classically strategies for the young and fit. Reduced-
intensity conditioning for allogeneic BMT is only one
example of a development that will bring medical condi-
tions such as renal, cardiac or vascular insufficiency to
the oncology wards and thus more patients with such
conditions and cancer to the ICU. How do we treat a
sepsis in a neutropenic patient that harbours several for-
eign bodies such as pace makers, PTFD shunts and total
endoprotheses? How do we dose novel targeted drugs in
patients with renal or hepatic failure undergoing SLEDD
(sustained slow-efficiency dialysis) or MARS (Molecular
Adsorbents Recirculation System) treatment? How to
dose anticoagulation in patients with atrial fibrillation
and thrombopenia on prothrombotic biologicals such as
lenalidomide?
These issues can only be addressed when medical
oncology and geriatric as well as intensive care medicine
start working closely together to develop common,
interdisciplinary algorithms.
An increasing number of novel drug classes is entering
the market and novel, unexpected serious adverse events
(SAE) are encountered [27-29]. A closer collaboration
between oncology wards and ICUs e.g. by using shared
beds might be a good environment to monitor and treat
patients receiving novel agents or dose levels. No inten-
sivist alone can anticipate rare side effects without an
in-depth knowledge of oncological drug actions. On the
c o n t r a r yo n c o l o g i s t sw i l lh a r d l yb ea b l et om a n a g e
severe adverse effects they have seen twice in their life-
time. Managing these problems together will not only
be safest for the patient but will also accelerate the
understanding of drug/patient interactions.
To date future intensive care patients frequently enter
the hospital via the emergency room in critical condi-
tions necessitating sedation and respiratory support. A
personal relationship to the ICU staff is therefore only
developed in select cases. Cancer patients are treated
long-term and personal relationships with the treating
nurses and physicians are common. If such patients
enter the ICU the physician-patient relationship
becomes extraordinarily difficult as the ICU days mean
much more suffering and pain than regular treatment. It
is hard to imagine that this stress can be tolerated by
the caregivers without long-term psychological damage
or at least specialized psychological guidance. ICUs spe-
cialized in the challenges of cancer medicine would have
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gies so far not existent in critical care.
The dynamic of this development is underlined by the
fact that substantial progress has already been made
both in intensive care and hematology/oncology which
already results in an improved survival of critically ill
cancer patients [30-32].
Discussion
To best address the above challenges we propose a four
step strategy:
1. Permissive ICU admission policies for cancer
patients and early and aggressive treatment has been
reported to be beneficial for cancer and non-cancer
patients alike [30,33,34]. Development of organ failure
has been shown to have a good predictive value con-
cerning the mortality [24,30,35]. Therefore, rapid and
comprehensive initiation of treatment should be fol-
lowed by a defined treatment phase which will allow to
observe development of disease severity, identify further
oncological treatment options and determine the prog-
nosis of the acute disease. After a defined period e.g. 4-6
days an interdisciplinary meeting consisting of oncolo-
gists, intensivists, nurses, psychologists, palliative care
and ethics specialists should be held to reevaluate the
situation and possibly redefine the treatment goals. In
most situations comprehensive interdisciplinary decision
making is not possible in the phase of ICU admission
due to occurrence during after hours or the need to act
immediately in emergencies. A reevaluation after a lim-
ited treatment phase appears to allow for more solid
judgment.
2. Oncologists spend more time talking to the patients
and their families than colleagues from many other spe-
cialties. However, the aspect of intensive care and resus-
citation are rarely addressed in these discussions.
Therefore, end-of-life decisions and do-not-resuscitate
orders are often issued by the treating intensivist alone
[36,37]. This is rather suboptimal as these decisions
often have to be made when the patient (and the family)
is barely able to participate in such a discussion and the
treating physician is under considerable stress (night
time work, urgency of situation, suffering patient etc.).
We suggest that the treating oncologist should address
ICU admission and code orders early to learn the
patient’sa n df a m i l y ’so p i n i o na n dt og i v et h e mt i m et o
consider. This information should help define prelimin-
ary treatment goals upon admission and refine them
after an early treatment phase of 4-6 days.
3. How can oncological knowledge best be brought to
the ICU and how can critical care be optimized for can-
cer patients? The already growing number of cancer
patients undergoing critical care currently necessitates a
‘distribution’ of these patients to IC wards of various
specialties. This development is viewed with concern,
not only by the patients and their families, but also by
the responsible physicians, and is certainly not a desir-
able development.
Oncologists and intensivists are usually distinct types
of physicians that clearly know why they do not want to
perform their colleagues’ work. While oncologist have
significant time to research and identify the optimal
strategies for their patients, intensivists sometimes need
to make quick decisions based on little or -on the con-
trary-, extremely complex, but inconclusive information.
Oncologists spend a lot of their time talking with
patients and families while intensivists focus on delicate,
invasive procedures. Therefore, they share little common
ground and patients either benefit from the one set of
skills or the other, rarely both at the same time.
The most obvious solution would be to have common
rounds and prime different mind sets by common rota-
tions during training. Intensivists should be encouraged
to acquire practical and theoretical knowledge of hae-
matology and oncology as part of their specialty training
and vice versa.
An alternative approach is being pursued at our
institution where a medical ICU (MICU) is integrated
into the oncology service. The department of medical
oncology is part of a regional comprehensive cancer
center and the MICU part of a portal for emergency
medicine and intensive care. Thus there are closest
interactions with neighboring specialties e.g. radiother-
apy, gastroenterology, palliative care, surgery, psychol-
ogy on the one hand and anesthesia, emergency
medicine, general as well as specialized surgical, neuro-
logical and cardiac intensive care on the other. The
ICU is directed by physicians that are trained medical
oncologists and intensive care specialists. An increas-
ing number of interns that were once dedicated to
become oncologists have now discovered their interest
and talent for the other specialty and are pursuing
such a double qualification. This is a development we
have anecdotally seen in the field of bone marrow
transplantation where haematologist had become
familiar with the treatment of their critically ill
patients due to isolation policies. However, in this sce-
nario few doctors treat highly selected, fit patients for
a limited number of ICU diagnoses such as sepsis or
neutropenic colitis. A third approach would be a core
training in one specialty and an supplementary educa-
tion in the other. Best such training should be imple-
mented in major medical centers as these often have a
culture of intensive training and sufficient resources to
develop and implement novel structures. If successful
this process can spread to other tertiary and even sec-
ondary medical centers. “Critical Cancer Care” can
only be developed as a joint effort by intensivists and
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be a two year secondary subspecialty training after
internal medicine/hematology/oncology or internal
medicine/intensive care or anesthesiology/intensive
care. Training should be organized by both specialities
and should consist of theoretical instruction in the
new subject and a common practical training including
rotations of e.g. six months to non critical cancer care
e.g. oncology clinic for intensivists and anesthesiology
for the oncologists. This is in contrast to other subspe-
cialties such as neurosurgical or cardiac critical care
that are based on skills taught in the “mother” speci-
alty and that are linked to acute medicine and critical
care on a daily basis. Also knowledge relevant to the
treatment of cardiologic patients is more familiar to
intensivists than the treatment of solid tumors.
To measure the impact of such a structure pilot medi-
cal centers should determine the ICU length of stay,
respirator days and in hospital mortality as well as
patient and referring oncologist satisfaction. The period
prior to the implementation of this specialty program
should be compared to the period thereafter.
Whichever approach will demonstrate successful it is
clear that the specialty of ’critical care of cancer patients’
needs to be recognized, defined and developed. The
foreseeable development of cancer medicine necessitates
that qualified critical care will eventually be available for
a rapidly growing number of cancer patients.
4. Most patients with advanced cancers are treated in
an outpatient setting by medical oncologists. However,
inpatient treatment is often performed by physicians
specialized in defined organ systems such as urologists,
pulmologists, gastroenterologists, gynecologists etc. It
appears to be most beneficial for the critically ill cancer
patients to bring these specialties into the above sce-
nario e.g. by regular consultations. First, they are needed
to participate in the treatment as referring oncologists
and second they can contribute expertise concerning
organ-specific complications such as airway stenosis,
bleeding from gastrointestinal tumors, urinary tract
obstruction etc.
Taken together, the number of cancer patients need-
ing critical care is dramatically rising and as a conse-
quence the array of open questions regarding the
optimal management of such patients is growing. These
uncertainties can only be addressed successfully when
t h eo n c o l o g ya n di n t e n s i v ec a r ec o m m u n i t i e ss t a r t
developing ‘critical cancer care’ concepts as a long-term,
joint effort.
Summary
Cancer medicine is rapidly improving and cancer is
eventually becoming a chronic disease. Oncology is
therefore characterized by a growing number of older
and medically unfit patients that receive numerous
novel drug classes with unexpected side effects. These
changes will most likely generate more medically chal-
lenging patients in acute distress that need to be consid-
ered for intensive care. An intense exchange between
intensivists, oncologists, psychologists and palliative care
specialists is warranted to communicate the develop-
ments in each field in order to improve triage and
patient treatment. We postulate that “critical care of
cancer patients” needs to be recognized as a medical
subspecialty and that there is an urgent need to develop
it systematically.
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